BMH BRÄUTIGAM ADVISES PRIMA BIOMED IN A$400 MILLION CROSS-BORDER SPIN OUT
BMH BRÄUTIGAM led a team comprising German, Australian and U.S.-American lawyers for out-licensing Prima BioMed’s CVac immuno-oncology through a cross-border spin out.
Prima BioMed is a globally active Sydney-based biotechnology company with branches in Germany and France. It is listed in Australia (ASX) and the United States (NASDAQ).
Licensee is U.S.-based and U.S.-listed Sydys Corporation. Along with the license for CVac, it acquired various CVac-related assets.
Prima BioMed receives performance-based payments up to A$400 million (US$ 293 million) as well as 9.9% equity stake in Sydys.
Prima Biomed is a loyal client of BMH BRÄUTIGAM. The contact was made by CEO Marc Voigt, who formerly served as board-member for Medical Enzymes AG.
Dr. Patrick Hohl has advised Medical Enzymes AG in various transactions.
BMH BRÄUTIGAM Team:
Dr. Patrick Hohl, Dr. Alexander Wulff, Katharina Erbe (M&A | Venture Capital)